TermorshuizenF., KorevaarJ.C., DekkerF.W., JagerK.J., van ManenJ.G., BoeschotenE.W.Time trends in initiation and dose of dialysis in end-stage renal disease patients in The Netherlands.Nephrol Dial Transplant2003; 18: 552–8.
2.
FeestT.G., RajamaheshJ., ByrneC., AhmadA., AnsellD., BurdenR.Trends in adult renal replacement therapy in the UK: 1982–2002.QJM2005; 98: 21–8.
3.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC., on behalf of the Euro Balance Trial Group. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
4.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
5.
KasaiK., TerawakiH., TannoY., HaraY., KondoM., HamaguchiA.Factors influencing residual renal function of CAPD patients.Nippon Jinzo Gakkai Shi1999; 41: 726–30.
